Radboud university medical center and UMC Utrecht are working on a joint research project to discover whether the tuberculosis (BCG) vaccine reduces the risk of infection with the coronavirus in people aged 60 or older, or the severity of the symptoms in the event of infection. A total of 1,600 people may take part in the study, which starts today. Half of the study participants will be given the vaccine, the other half will not.
The elderly have a higher chance of becoming seriously ill as a result of the coronavirus. Also, if infected, they are more at risk of dying from the infection. There is currently no vaccine against the coronavirus, and no other way of protecting the elderly from infection. However, previous research shows that the BCG vaccine protects not just against tuberculosis, but that it can also increase people’s immunity to other viruses.
It is unclear whether the BCG vaccine can also provide some level of protection from the coronavirus. The aim of this study is therefore to find out whether it does. The study should answer the question whether the BCG vaccine provides protection from the coronavirus and/or whether it reduces the severity of the symptoms in the elderly. This is the second study carried out by the Radboud university medical center and UMC Utrecht into the effect of the BCG vaccine on the coronavirus. The first study focused specifically on healthcare workers, whereas this study focuses exclusively on the elderly.
BCG is the most widely administered vaccine in the world and is used in many countries to prevent tuberculosis. For this study, the hospitals will obtain the BCG vaccine directly from the Dutch National Institute for Public Health and the Environment (RIVM). The study will therefore not affect the availability of the vaccine for regular use by the municipal public health service (GGD) in the Netherlands. Participants in the study must be aged 60 or older.
Related news items
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.read more
Oral health research makes significant impact at the 148th WHO Executive Board meeting25 January 2021
During the 148th session of the World Health Organization (WHO) Executive Board meeting, Member States passed a game-changing resolution on oral health. WHO Director General Dr Tedros Adhanom Ghebreyesus called it a “landmark resolution”.read more
Radboud Young Academy safeguards the future of science21 January 2021
New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.read more
Increase radio- and immunotherapy efficacy by targeting hypoxia21 January 2021
In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.read more
Radiation boost lowers risk of prostate cancer recurrence21 January 2021
An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.read more
New research through grants for Radboudumc researchers14 January 2021
Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.read more